<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD11530000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q99814</UniProt_ID>
  <Seq_Length>870</Seq_Length>
  <Molecule_Weight>96459</Molecule_Weight>
  <KEGG_ID>hsa:2034</KEGG_ID>
  <Orthology_ID>K09095</Orthology_ID>
  <EBI_ID>EBI-447470</EBI_ID>
  <Function_Summary>Transcription factor involved in the induction of oxygen regulated genes. Binds to core DNA sequence 5'-[AG]CGTG-3' within the hypoxia response element (HRE) of target gene promoters. Regulates the vascular endothelial growth factor (VEGF) expression and seems to be implicated in the development of blood vessels and the tubular system of lung. May also play a role in the formation of the endothelium that gives rise to the blood brain barrier. Potent activator of the Tie-2 tyrosine kinase expression. Activation seems to require recruitment of transcriptional coactivators such as CREBPB and probably EP300. Interaction with redox regulatory protein APEX seems to activate CTAD.</Function_Summary>
  <Pfam_ID>PF11413:HIF-1@@PF08778:HIF-1a_CTAD@@PF00989:PAS</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>9</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>1</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>bHLHe73</Alias>
      <Alias>Member of PAS protein 2</Alias>
      <Alias>PAS domain-containing protein 2</Alias>
      <Alias>HIF2-alpha</Alias>
      <Alias>HLF</Alias>
      <Alias>HIF-2-alpha</Alias>
      <Alias>HIF-1-alpha-like factor</Alias>
      <Alias>Hypoxia-inducible factor 2-alpha</Alias>
      <Alias>Class E basic helix-loop-helix protein 73</Alias>
      <Alias>EPAS-1</Alias>
      <Alias>Basic-helix-loop-helix-PAS protein MOP2</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Conveys a signal across a cell to trigger a change in cell function or state. A signal is a physical entity or change in state that is used to transfer information in order to trigger a response.</Detail>
      <Keyword>Signal transducer activity</Keyword>
      <Ontology_ID>GO:0004871</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nonidentical protein to form a heterodimer.</Detail>
      <Keyword>Protein heterodimerization activity</Keyword>
      <Ontology_ID>GO:0046982</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Protein that positively regulates either the transcription of one or more genes, or the translation of mRNA.</Detail>
      <Keyword>Activator</Keyword>
      <Ontology_ID>KW-0010</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the enzyme histone acetyltransferase.</Detail>
      <Keyword>Histone acetyltransferase binding</Keyword>
      <Ontology_ID>GO:0035035</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a transcription factor, any protein required to initiate or regulate transcription.</Detail>
      <Keyword>Transcription factor binding</Keyword>
      <Ontology_ID>GO:0008134</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a sequence of DNA that is in cis with and relatively close to a core promoter for RNA polymerase II (RNAP II) in order to activate or increase the frequency, rate or extent of transcription from the RNAP II promoter.</Detail>
      <Keyword>RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription</Keyword>
      <Ontology_ID>GO:0001077</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Modulation of the frequency, rate or extent of transcription from an RNA polymerase II promoter as a result of a stimulus indicating the organism is under oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals.</Detail>
      <Keyword>Regulation of transcription from RNA polymerase II promoter in response to oxidative stress</Keyword>
      <Ontology_ID>GO:0043619</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The reorganization or renovation of existing blood vessels.</Detail>
      <Keyword>Blood vessel remodeling</Keyword>
      <Ontology_ID>GO:0001974</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase II promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0045944</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving norepinephrine, a hormone secreted by the adrenal medulla, and a neurotransmitter in the sympathetic peripheral nervous system and in some tracts in the central nervous system. It is also the demethylated biosynthetic precursor of epinephrine.</Detail>
      <Keyword>Norepinephrine metabolic process</Keyword>
      <Ontology_ID>GO:0042415</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A developmental process, independent of morphogenetic (shape) change, that is required for a cell to attain its fully functional state.</Detail>
      <Keyword>Cell maturation</Keyword>
      <Ontology_ID>GO:0048469</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a mitochondrion; includes mitochondrial morphogenesis and distribution, and replication of the mitochondrial genome as well as synthesis of new mitochondrial components.</Detail>
      <Keyword>Mitochondrion organization</Keyword>
      <Ontology_ID>GO:0007005</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which the developmental fate of a cell becomes restricted such that it will develop into a myoblast cell. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.</Detail>
      <Keyword>Myoblast cell fate commitment</Keyword>
      <Ontology_ID>GO:0048625</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.</Detail>
      <Keyword>Response to hypoxia</Keyword>
      <Ontology_ID>GO:0001666</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The synthesis of RNA from a DNA template by RNA polymerase II (Pol II), originating at a Pol II-specific promoter. Includes transcription of messenger RNA (mRNA) and certain small nuclear RNAs (snRNAs).</Detail>
      <Keyword>Transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0006366</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.</Detail>
      <Keyword>Cellular response to hypoxia</Keyword>
      <Ontology_ID>GO:0071456</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal, e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light, and ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell, and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.</Detail>
      <Keyword>Signal transduction</Keyword>
      <Ontology_ID>GO:0007165</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the lung over time, from its formation to the mature structure. In all air-breathing vertebrates the lungs are developed from the ventral wall of the oesophagus as a pouch which divides into two sacs. In amphibians and many reptiles the lungs retain very nearly this primitive sac-like character, but in the higher forms the connection with the esophagus becomes elongated into the windpipe and the inner walls of the sacs become more and more divided, until, in the mammals, the air spaces become minutely divided into tubes ending in small air cells, in the walls of which the blood circulates in a fine network of capillaries. In mammals the lungs are more or less divided into lobes, and each lung occupies a separate cavity in the thorax.</Detail>
      <Keyword>Lung development</Keyword>
      <Ontology_ID>GO:0030324</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a myeloid precursor cell acquires specializes features of an erythrocyte.</Detail>
      <Keyword>Erythrocyte differentiation</Keyword>
      <Ontology_ID>GO:0030218</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.</Detail>
      <Keyword>Cell differentiation</Keyword>
      <Ontology_ID>GO:0030154</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of a steady-state level of the surface-active lipoprotein mixture which coats the alveoli.</Detail>
      <Keyword>Surfactant homeostasis</Keyword>
      <Ontology_ID>GO:0043129</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The biological process whose specific outcome is the progression of a multicellular organism over time from an initial condition (e.g. a zygote or a young adult) to a later condition (e.g. a multicellular animal or an aged adult).</Detail>
      <Keyword>Multicellular organismal development</Keyword>
      <Ontology_ID>GO:0007275</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels.</Detail>
      <Keyword>Angiogenesis</Keyword>
      <Ontology_ID>GO:0001525</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of events required for an organism to receive a visual stimulus, convert it to a molecular signal, and recognize and characterize the signal. Visual stimuli are detected in the form of photons and are processed to form an image.</Detail>
      <Keyword>Visual perception</Keyword>
      <Ontology_ID>GO:0007601</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency or rate of heart contraction.</Detail>
      <Keyword>Regulation of heart rate</Keyword>
      <Ontology_ID>GO:0002027</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The embryonically driven process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin.</Detail>
      <Keyword>Embryonic placenta development</Keyword>
      <Ontology_ID>GO:0001892</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>405</Position>
      <PTM_Type>4-hydroxyproline</PTM_Type>
    </PTM>
    <PTM>
      <Position>840</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>531</Position>
      <PTM_Type>4-hydroxyproline</PTM_Type>
    </PTM>
    <PTM>
      <Position>847</Position>
      <PTM_Type>(3S)-3-hydroxyasparagine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MTADKEKKRSSSERRKEKSRDAARCRRSKETEVFYELAHELPLPHSVSSHLDKASIMRLAISFLRTHKLLSSVCSENESEAEADQQMDNLYLKALEGFIAVVTQDGDMIFLSENISKFMGLTQVELTGHSIFDFTHPCDHEEIRENLSLKNGSGFGKKSKDMSTERDFFMRMKCTVTNRGRTVNLKSATWKVLHCTGQVKVYNNCPPHNSLCGYKEPLLSCLIIMCEPIQHPSHMDIPLDSKTFLSRHSMDMKFTYCDDRITELIGYHPEELLGRSAYEFYHALDSENMTKSHQNLCTKGQVVSGQYRMLAKHGGYVWLETQGTVIYNPRNLQPQCIMCVNYVLSEIEKNDVVFSMDQTESLFKPHLMAMNSIFDSSGKGAVSEKSNFLFTKLKEEPEELAQLAPTPGDAIISLDFGNQNFEESSAYGKAILPPSQPWATELRSHSTQSEAGSLPAFTVPQAAAPGSTTPSATSSSSSCSTPNSPEDYYTSLDNDLKIEVIEKLFAMDTEAKDQCSTQTDFNELDLETLAPYIPMDGEDFQLSPICPEERLLAENPQSTPQHCFSAMTNIFQPLAPVAPHSPFLLDKFQQQLESKKTEPEHRPMSSIFFDAGSKASLPPCCGQASTPLSSMGGRSNTQWPPDPPLHFGPTKWAVGDQRTEFLGAAPLGPPVSPPHVSTFKTRSAKGFGARGPDVLSPAMVALSNKLKLKRQLEYEEQAFQDLSGGDPPGGSTSHLMWKRMKNLRGGSCPLMPDKPLSANVPNDKFTQNPMRGLGHPLRHLPLPQPPSAISPGENSKSRFPPQCYATQYQDYSLSSAHKVSGMASRLLGPSFESYLLPELTRYDCEVNVPVLGSSTLLQGGDLLRALDQAT</Protein_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Transcription factor complex</CellLocal>
      <Ontology_ID>GO:0005667</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
      <Ontology_ID>GO:0005829</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleoplasm</CellLocal>
      <Ontology_ID>GO:0005654</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>EPAS1</Gene_Name>
    <Gene_Alias>BHLHE73; HIF2A; MOP2; PASD2</Gene_Alias>
    <Gene_ID>2034</Gene_ID>
    <Genbank_ACCN>NM_001430</Genbank_ACCN>
    <Protein_ACCN>NP_001421</Protein_ACCN>
    <HGNC_ID>3374</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/2034</Gene_URL>
    <UCSC_ID>uc002ruv.3</UCSC_ID>
    <EMBL_ID>ENSG00000116016</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P61244</Uniprot_ID>
      <Gene_Name>MAX</Gene_Name>
      <EBI_ID>EBI-751711</EBI_ID>
      <PPI_EBI_URL>EBI-447470,EBI-751711</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9GZT9</Uniprot_ID>
      <Gene_Name>EGLN1</Gene_Name>
      <EBI_ID>EBI-1174818</EBI_ID>
      <PPI_EBI_URL>EBI-447470,EBI-1174818</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P60228</Uniprot_ID>
      <Gene_Name>EIF3E</Gene_Name>
      <EBI_ID>EBI-347740</EBI_ID>
      <PPI_EBI_URL>EBI-447470,EBI-347740</PPI_EBI_URL>
      <Experiment_Number>10</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P08047</Uniprot_ID>
      <Gene_Name>SP1</Gene_Name>
      <EBI_ID>EBI-298336</EBI_ID>
      <PPI_EBI_URL>EBI-447470,EBI-298336</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q96RK4</Uniprot_ID>
      <Gene_Name>BBS4</Gene_Name>
      <EBI_ID>EBI-1805814</EBI_ID>
      <PPI_EBI_URL>EBI-447470,EBI-1805814</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P40818</Uniprot_ID>
      <Gene_Name>USP8</Gene_Name>
      <EBI_ID>EBI-1050865</EBI_ID>
      <PPI_EBI_URL>EBI-447470,EBI-1050865</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Sporadic Secreting Paraganglioma</Disease_Name>
      <Disease_Detail>Sporadic Secreting Paraganglioma</Disease_Detail>
      <Disease_DB>SPR069</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/sporadic_secreting_paraganglioma?search=EPAS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pheochromocytoma</Disease_Name>
      <Disease_Detail>Pheochromocytoma</Disease_Detail>
      <Disease_DB>PHC003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pheochromocytoma?search=EPAS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Sporadic Pheochromocytoma</Disease_Name>
      <Disease_Detail>Sporadic Pheochromocytoma</Disease_Detail>
      <Disease_DB>SPR094</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/sporadic_pheochromocytoma?search=EPAS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Nodular Malignant Melanoma</Disease_Name>
      <Disease_Detail>Nodular Malignant Melanoma</Disease_Detail>
      <Disease_DB>NDL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/nodular_malignant_melanoma?search=EPAS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Erythrocytosis 4</Disease_Name>
      <Disease_Detail>Familial Erythrocytosis</Disease_Detail>
      <Disease_DB>FML121</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_erythrocytosis_4?search=EPAS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vein Disease</Disease_Name>
      <Disease_Detail>Vein Disease</Disease_Detail>
      <Disease_DB>VND001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vein_disease?search=EPAS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Multiple Paragangliomas Associated with Polycythemia</Disease_Name>
      <Disease_Detail>Multiple Paragangliomas Associated with Polycythemia</Disease_Detail>
      <Disease_DB>MLT106</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/multiple_paragangliomas_associated_with_polycythemia?search=EPAS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Erythrocytosis 3</Disease_Name>
      <Disease_Detail>Familial Erythrocytosis</Disease_Detail>
      <Disease_DB>FML120</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_erythrocytosis_3?search=EPAS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Somatostatinoma</Disease_Name>
      <Disease_Detail>Somatostatinoma</Disease_Detail>
      <Disease_DB>SMT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/somatostatinoma?search=EPAS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypoxia</Disease_Name>
      <Disease_Detail>Hypoxia</Disease_Detail>
      <Disease_DB>HYP266</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypoxia?search=EPAS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Erythrocytosis</Disease_Name>
      <Disease_Detail>Erythrocytosis</Disease_Detail>
      <Disease_DB>ERY013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/erythrocytosis?search=EPAS1#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains with the artificial ligand THS020</PDB_Title>
      <PDB_ID>3H82</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3H82</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11530008</ASD_Ligand>
      <PubMed_Title>Principles of ligand binding within a completely buried cavity in HIF2alpha PAS-B</PubMed_Title>
      <Author>Key, J., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2009)131:17647-17654</Journal>
      <PubMed_ID>19950993</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains, with an internally-bound artificial ligand</PDB_Title>
      <PDB_ID>3F1O</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3F1O</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11530005</ASD_Ligand>
      <PubMed_Title>Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor.</PubMed_Title>
      <Author>Scheuermann, T.H., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2009)106:450-455</Journal>
      <PubMed_ID>19129502</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains with the artificial ligand THS017</PDB_Title>
      <PDB_ID>3H7W</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3H7W</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11530004</ASD_Ligand>
      <PubMed_Title>Principles of ligand binding within a completely buried cavity in HIF2alpha PAS-B</PubMed_Title>
      <Author>Key, J., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2009)131:17647-17654</Journal>
      <PubMed_ID>19950993</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains in complex with an inactive benzoxadiazole antagonist</PDB_Title>
      <PDB_ID>4GS9</PDB_ID>
      <Resolution>1.72</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4GS9</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11530010</ASD_Ligand>
      <PubMed_Title>Development of Inhibitors of the PAS-B Domain of the HIF-2 alpha Transcription Factor</PubMed_Title>
      <Author>Rogers, J.L., et al.</Author>
      <Journal>J.Med.Chem.(2013)56:1739-1747</Journal>
      <PubMed_ID>23363003</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the high affinity heterodimer of HIF2 alpha and ARNT C-terminal PAS domains in complex with a benzoxadiazole antagonist</PDB_Title>
      <PDB_ID>4GHI</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4GHI</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11530009</ASD_Ligand>
      <PubMed_Title>Allosteric inhibition of hypoxia inducible factor-2 with small molecules.</PubMed_Title>
      <Author>Scheuermann, T.H., et al.</Author>
      <Journal>Nat.Chem.Biol.(2013)9:271-276</Journal>
      <PubMed_ID>23434853</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05211</Pathway_ID>
      <Pathway_Title>Renal cell carcinoma</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05211</Pathway_ID>
      <Pathway_Title>Renal cell carcinoma</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
  </Network_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD11530001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11530002</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11530003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11530004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11530005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11530006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11530007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11530008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11530009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11530010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2014-06-12</Create_Date>
</Organism_Record>